Zydus Lifesciences has received a No Objection Certificate from Health Canada for its ZDS-Varenicline tablets.
Varenicline is used to help people quit smoking. It works by partially activating nicotine receptors in the brain while blocking nicotine's effects.
According to IQVIA MAT December 2024 data, Varenicline tablets recorded annual sales of CAD 15 million in the Canadian market.
Zydus Lifesciences on Thursday said it has received a no objection certificate (NOC) from Health Canada for a product used to help quit smoking.
The company has received NOC for ZDS-Varenicline tablets (0.5 &1 mg), Zydus Lifesciences said in a statement.
Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain.
ZDS-Varenicline tablets will be produced at Zydus Lifescience Ltd, SEZ, Ahmedabad, the drugmaker said.
As per IQVIA MAT December 2024 data, Varenicline tablets had annual sales of CAD 15 million in the Canadian market.
